Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

WideCells appoints Dr Jeremy Lea as chief operating officer

"As the business develops, we believe Jeremy will be invaluable on continuing this positive trajectory," said João Andrade, the chief executive officer of WideCells
Medical centre
Dr Lea will be based in Manchester, where the group's Institute of Stem Cell Technology is based

Dr Jeremy Lea is the new chief operating officer (COO) of WideCells Group PLC (LON:WDC), replacing Lopes Gill, who is stepping down for personal reasons.

Dr Lea will be responsible for leading the group's next phase of growth as it builds revenues and drives the global uptake of its innovative portfolio of stem cell services, including: CellPlan, the world's first stem cell healthcare insurance plan; WideCells, which is focused on stem cell storage services, and Wideacademy, the group's education and training division.

READ: Widecells says trading is strong

Dr Lea has extensive sales and management experience and success in delivering tangible financial, operational and efficiency-driven improvements within the healthcare sector, WideCells said.

He already has an in-depth understanding of the group, having led WideCells Limited, the group's stem cell storage and research division, and has also helped in a number of senior management positions.

Lopes may be stepping down but will remain with the group as an advisor. Similarly, non-executive director Dr Marilyn Orcharton is stepping down from the board but will assume an advisory role to support the building of the group's dental-related stem cell services, which will include the launch of a new stem cell storage service, TeethCells.

João Andrade, the chief executive officer of WideCells, thanks Lopes and Orcharton for their contribution to the company.

"Having worked with Jeremy, we understand his ability to develop commercial models and the operations around them. His understanding of our business, commercial acumen, global sales experience and knowledge of the healthcare sector make him well qualified to assume the role of group COO as we look to deliver significant revenue, profit and market share growth,” Andrade said.

“We have now completed our first sales for BabyCells (stem cell storage) and CellPlan (stem cell insurance) in the UK, which enabled us to complete full sales cycles for both products, placing us in a better position to grow our sales in the domestic and international markets. In the near term, this will include driving sales of our recently launched stem cell storage services, operated from our Institute of Stem Cell Technology in Manchester, where Jeremy will be based. We also continue to target additional sales agreements for our CellPlan insurance product, with a prospective opportunity identified in Portugal where this division is based,” Andrade said.  

Change to shareholdings following the recent share placing

The company said that asset management firm Miton Group has increased its stake in the company to 11.06% following the purchase of 8.33mln shares as a result of participating in the recent share placing by WideCells.

Smaller Company Capital, which took 5mln shares in the fund-raising, has increased its holding in the company to 4.95%.

 

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use